Title:Neuropsychiatric Manifestations in Alzheimer’s Disease Patients: Genetics
and Treatment Options
Volume: 23
Issue: 1
Author(s): Arun Kumar Singh, Rishabha Malviya*, Anuj Prakash and Swati Verma
Affiliation:
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University Greater Noida, Uttar Pradesh,
India
Keywords:
Alzheimer’s disease, genetic manipulation, neurological disorder, psychosis, dementia, delusions.
Abstract:
Background: Alzheimer's disease (AD) is characterized by neuropsychiatric symptoms
(NPS), which cause great misery to those with dementia and those who care for them and may lead to
early institutionalization.
Objective: The present systematic review aims to discuss the various aspects of Alzheimer’s, including
treatment options.
Methods: The databases Embase, PubMed, and Web of Science were searched to collect data.
Results: Incipient cognitive deterioration is commonly accompanied by these early warning signals of
neurocognitive diseases. The neurobiology of NPSs in Alzheimer's disease, as well as particular symptoms,
including psychosis, agitation, apathy, sadness, and sleep disorders, will be examined in this review.
For NPSs in Alzheimer's disease, clinical trial designs, as well as regulatory issues, were also
addressed. A fresh wave of research, however, is helping to push the discipline ahead. For medication
development and repurposing, we highlight the most recent results in genetics, neuroimaging, and neurobiology.
Even though identifying and treating psychosis in adults with dementia is still a challenging
endeavor, new options are coming up that give the field fresh focus and hope.
Conclsuion: It can be concluded from the complete literature survey that Alzheimer's-related psychosis
as well as other symptoms that are not psychotic, have made significant progress in the last decade.
These milestones in the development of safer, more effective treatments have been achieved as a consequence
of great focus on non-pharmacological interventions like DICE or WHELD; the investigation
into ways to improve existing drugs like aripiprazole, risperidone, amisulpride, and Escitalopram
for safer precision-based treatment; and the development of a clinical trial program for pimavanserin.
